Eric Van Den Neste

2.8k total citations
79 papers, 1.6k citations indexed

About

Eric Van Den Neste is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Eric Van Den Neste has authored 79 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Genetics, 29 papers in Oncology and 22 papers in Pathology and Forensic Medicine. Recurrent topics in Eric Van Den Neste's work include Chronic Lymphocytic Leukemia Research (42 papers), Lymphoma Diagnosis and Treatment (20 papers) and Cancer-related Molecular Pathways (12 papers). Eric Van Den Neste is often cited by papers focused on Chronic Lymphocytic Leukemia Research (42 papers), Lymphoma Diagnosis and Treatment (20 papers) and Cancer-related Molecular Pathways (12 papers). Eric Van Den Neste collaborates with scholars based in Belgium, United States and France. Eric Van Den Neste's co-authors include Françoise Bontemps, Augustin Ferrant, Caroline Smal, Lucienne Michaux, S. Cardoen, Pascale Saussoy, Dominique Bron, Philippe Martiat, Benjamin Haibe‐Kains and Pierre Heimann and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Eric Van Den Neste

78 papers receiving 1.6k citations

Peers

Countries citing papers authored by Eric Van Den Neste

Since Specialization

Citations

This map shows the geographic impact of Eric Van Den Neste's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Van Den Neste with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Van Den Neste more than expected).

Fields of papers citing papers by Eric Van Den Neste

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Van Den Neste. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Van Den Neste. The network helps show where Eric Van Den Neste may publish in the future.

Co-authorship network of co-authors of Eric Van Den Neste

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Van Den Neste. A scholar is included among the top collaborators of Eric Van Den Neste based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Van Den Neste. Eric Van Den Neste is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study) 2024 ·British Journal of Haematology ·Florence Nguyen‐Khac, Marine Baron, Romain Guièze, Pierre Feugier, (unknown), Sophie Raynaud, Xavier Troussard, Nathalie Droin, Frédérik Damm, (unknown), Santos A. Susín, Véronique Leblond, Caroline Dartigeas, Eric Van Den Neste, (unknown), Olivier Bernard, Damien Roos‐Weil	2
2	Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper 2022 ·Hematological Oncology ·Sarah Bailly, Guillaume Cartron, Sridhar Chaganti, Raúl Córdoba, Paolo Corradini, (unknown), Isacco Ferrarini, Wendy Osborne, Andreas Rosenwald, Juan‐Manuel Sancho, Hervé Tilly, Eric Van Den Neste, Andreas Viardot, Carlo Visco	10
3	Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts) 2021 ·Blood ·Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, Krish Patel, Cyrus Khan, Nancy L. Bartlett, Gloria Iacoboni, Mark Hertzberg, Sirpa Leppä, Eric Van Den Neste, Monica Tani, Guillaume Cartron, Antonio Salar, David Pérez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings	9
4	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma 2021 ·Blood Advances ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jaeyeon Kim, Christian Gisselbrecht	45
5	Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study 2017 ·Psycho-Oncology ·Yves Libert, (unknown), Yves Béguin, Nicole Delvaux, Martine Devos, Chantal Doyen, (unknown), Anne-Marie Étienne, Aurore Liénard, Isabelle Merckaert, Christine Reynaert, Jean‐Louis Slachmuylder, Nicole Straetmans, Eric Van Den Neste, Dominique Bron, Darius Razavi	3
6	Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types 2017 ·BMJ Open ·Caroline Lonez, Bikash Verma, Alain Hendlisz, Philippe Aftimos, Ahmad Awada, Eric Van Den Neste, (unknown), Jean‐Pascal Machiels, Fanny Piette, Jason Brayer, David A. Sallman, Tessa Kerre, Kunle Odunsi, Marco L. Davila, David E. Gilham, Frédéric Lehmann	42
7	Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant 2013 ·Haematologica ·Eric Van Den Neste, Olivier Casasnovas, Marc André, Mohamed Touati, Delphine Sénécal, Véronique Edeline, Aspasia Stamatoullas, Luc Mathieu Fornecker, Bénédicte Deau, (unknown), Oumédaly Reman, Isabelle Gaillard, Cécile Borel, Pauline Brice, Christophe Fermé	35
8	Phosphorylation of deoxycytidine kinase on Ser-74: Impact on kinetic properties and nucleoside analog activation in cancer cells 2012 ·Biochemical Pharmacology ·(unknown), Eric Van Den Neste, (unknown), (unknown), Françoise Bontemps, Caroline Smal	11
9	Microrna-29c and 223 and Their Prognostic Value in Chronic Lymphocytic Leukemia 2009 ·Basile Stamatopoulos, Pascale Saussoy, Eric Van Den Neste, Lucienne Michaux, (unknown), Benjamin Haibe‐Kains, Peter Heimann, Philippe Martiat, Dominique Bron, Laurence Lagneaux	1
10	microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification 2009 ·Blood ·Basile Stamatopoulos, Nathalie Meuleman, Benjamin Haibe‐Kains, Pascale Saussoy, Eric Van Den Neste, Lucienne Michaux, Pierre Heimann, Philippe Martiat, Dominique Bron, Laurence Lagneaux	188
11	Improvement in Fatigue With Eculizumab Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (pnh) Occurs Independent of Changes in Anemia 2008 ·Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) ·Anita Hill, Eric Van Den Neste, Petra Muus, Ulrich Duehrsen, Gèrard Socié, (unknown), R. de Paz, Andréa Zanella, Jiaming Lai, Peter Hillmen, Russell P. Rother, David Cella	3
12	The clinical benefit of eculizumab is demonstrable in all subpopulations of patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis 2007 ·Petra Muus, Eric Van Den Neste, Ulrich Duehrsen, Modupe Elebute, Paul Browne, Álvaro Urbano-Ispizúa, Steven Coutré, R. de Paz, Barbara A. Konkle, (unknown), (unknown), Andréa Zanella, Peter Hillmen, (unknown), (unknown)	1
13	Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells 2004 ·Biochemical Pharmacology ·Caroline Smal, S. Cardoen, Luc Bertrand, (unknown), Augustin Ferrant, Georges Berghe, Eric Van Den Neste, Françoise Bontemps	26
14	Effects of 2‐Chloro‐2′‐Deoxyadenosine on the Cell Cycle in the Human Leukemia EHEB Cell Line 2004 ·Nucleosides Nucleotides & Nucleic Acids ·S. Cardoen, Eric Van Den Neste, Caroline Smal, Jean-François Rosier, Augustin Ferrant, Greet Van den Berghe, Françoise Bontemps	5
15	Activation of deoxycytidine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes 2003 ·Biochemical Pharmacology ·Eric Van Den Neste, Caroline Smal, S. Cardoen, (unknown), (unknown), Augustin Ferrant, Georges Berghe, Françoise Bontemps	27
16	2-Chloro-2′-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes 2002 ·Leukemia ·Eric Van Den Neste, S. Cardoen, (unknown), (unknown), (unknown), Augustin Ferrant, Greet Van den Berghe, Françoise Bontemps	17
17	ANGIOIMMUNOBLASTIC LYMPHADENOPATHY FOLLOWING CIPROFLOXACIN ADMINISTRATION 2002 ·Acta Clinica Belgica ·L. Knoops, Eric Van Den Neste, J. Hamels, (unknown), Philippe Mineur	2
18	Limited Activity of Mini-Dose Interferon α-2a in the Treatment of Myelodysplastic Syndrome 1996 ·Leukemia & lymphoma ·Marie Maerevoet, Eric Van Den Neste, André Delannoy, Augustin Ferrant, Philippe Martiat, André Bosly, M Fauchet, Jl. Michaux	1
19	Cyclosporine-a (cy A) Has Only Marginal Antileukemic Activity in Refractory Chronic Lymphocytic-leukemia (cll) 1994 ·Blood ·Eric Van Den Neste, Augustin Ferrant, Marie Maerevoet, Philippe Martiat, André Delannoy, Nicole Straetmans, Jl. Michaux	1
20	2-chloro-deoxyadenosine With Or Without Daunorubicin for Relapsing Or Refractory Acute Myeloblastic-leukemia 1993 ·Blood ·Eric Van Den Neste, Augustin Ferrant, André Delannoy, Philippe Mineur, (unknown), André Bosly, Philippe Martiat, A. Zenebergh, Jl. Michaux	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact